An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity | Zendy

Tim Wirt | Zendy; Sophia Roßkopf | Zendy; Thies Rösner | Zendy; Klara Marie Eichholz | Zendy; A. J. Kahrs | Zendy; Sebastian Lutz | Zendy; Anna Kretschmer | Zendy; Thomas Valerius | Zendy; Katja Klausz | Zendy; Anna Otte | Zendy; Martin Gramatzki | Zendy; Matthias Peipp | Zendy; Christian Kellner | Zendy

Open Access

An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity

Author(s) -

Tim Wirt,

Sophia Roßkopf,

Thies Rösner,

Klara Marie Eichholz,

A. J. Kahrs,

Sebastian Lutz,

Anna Kretschmer,

Thomas Valerius,

Katja Klausz,

Anna Otte,

Martin Gramatzki,

Matthias Peipp,

Christian Kellner

Publication year - 2017

Publication title -

transfusion medicine and hemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.971

H-Index - 39

eISSN - 1660-3818

pISSN - 1660-3796

DOI - 10.1159/000479978

Subject(s) - antibody dependent cell mediated cytotoxicity , antibody , fucosylation , cytotoxicity , fragment crystallizable region , complement dependent cytotoxicity , protein engineering , cd20 , chemistry , fucose , monoclonal antibody , microbiology and biotechnology , cancer research , immunology , biology , biochemistry , glycoprotein , in vitro , enzyme

Engineering of the antibody's fragment crystallizable (Fc) by modifying the amino acid sequence (Fc protein engineering) or the glycosylation pattern (Fc glyco-engineering) allows enhancing effector functions of tumor targeting antibodies. Here, we investigated whether complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) of CD20 antibodies could be improved simultaneously by combining Fc protein engineering and glyco-engineering technologies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research